Axial Spondyloarthritis (axSpA) Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

 Breaking News
  • No posts were found

Axial Spondyloarthritis (axSpA) Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

April 28
00:46 2023
Axial Spondyloarthritis (axSpA) Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Axial Spondyloarthritis (axSpA) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Axial Spondyloarthritis (axSpA) Pipeline Insight, 2023”, report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Axial Spondyloarthritis (axSpA) Market. 

The Axial Spondyloarthritis (axSpA) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Axial Spondyloarthritis (axSpA) Pipeline Analysis

Axial Spondyloarthritis (axSpA) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Axial Spondyloarthritis (axSpA) and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Axial Spondyloarthritis (axSpA) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Axial Spondyloarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular

  • Intraocular

  • Intrathecal 

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Axial Spondyloarthritis (axSpA) Therapeutic Segment @

Axial Spondyloarthritis (axSpA) Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Axial Spondyloarthritis. Currently, Affibody is leading the therapeutics market with its Axial Spondyloarthritis drug candidates in the most advanced stage of clinical development.

Latest Key Development in the Axial Spondyloarthritis (axSpA) Therapeutics Landscape

On 26 April 2023, Galapagos NV (Euronext & NASDAQ: GLPG) announced that the first patient was randomized in OLINGUITO, the pivotal Phase 3 program of filgotinib in AxSpA. Topline results are expected in H2 2025. In the Phase 2 TORTUGA study, filgotinib 200mg achieved significantly greater improvements in Ankylosing Spondylitis Disease Activity Score (ASDAS)1 at Week 12, the primary endpoint, and had an encouraging safety profile in patients with active r-AxSpA who had not responded to conventional treatment.

The Leading Players in the Axial Spondyloarthritis (axSpA) Therapeutics Market Include

AbbVie, Affibody, Amgen, Boehringer Ingelheim, Celgene, Clover Biopharmaceuticals, Eli Lilly and Company, Genrix Biopharmaceuticals, Horizon Pharma, Inmagene Biopharmaceuticals, Iroko Pharmaceuticals, Izana Bioscience, Janssen Biotech, Jiangsu Hengrui Medicine Co., Kinevant Sciences, Kyowa Kirin, Pfizer, Pozen, Roivant Sciences, Sun Pharmaceutical Industries, Suzhou Zelgen Biopharmaceuticals, Syntex Pharmaceuticals, and others.

Axial Spondyloarthritis (axSpA) Therapies Covered in the Report Include:

  • ABY-035: Affibody

  • Bimekizumab: UCB Biopharma

  • CC-99677: Celgene

  • Cosentyx: Novartis

  • Humira (adalimumab): AbbVie

  • Jaktinib: Suzhou Zelgen Biopharmaceuticals

  • Namilumab: Izana Bioscience

  • SCB-808: Clover Biopharmaceuticals

  • Taltz (ixekizumab): Eli Lilly and Company

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Axial Spondyloarthritis (axSpA) Current Treatment Patterns

4. Axial Spondyloarthritis (axSpA) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Axial Spondyloarthritis (axSpA) Late Stage Products (Phase-III)

7. Axial Spondyloarthritis (axSpA) Mid-Stage Products (Phase-II)

8. Axial Spondyloarthritis (axSpA) Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Axial Spondyloarthritis (axSpA) Discontinued Products

13. Axial Spondyloarthritis (axSpA) Product Profiles

14. Key Companies in the Axial Spondyloarthritis (axSpA) Market

15. Key Products in the Axial Spondyloarthritis (axSpA) Therapeutics Segment

16. Dormant and Discontinued Products

17. Axial Spondyloarthritis (axSpA) Unmet Needs

18. Axial Spondyloarthritis (axSpA) Future Perspectives

19. Axial Spondyloarthritis (axSpA) Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles